Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact
Shorla Oncology

Shorla Oncology Achieves Great Place to Work Certification

March 26th 2024

Read More

Logo

FDA Receives New Drug Application for SH-105 in Breast and Ovarian Cancer

January 15th 2024January 15th 2024

Read More

Logo

OncLive/ SH-105 Gets Accepted for FDA Review in Breast and Ovarian Cancer

January 15th 2024January 15th 2024

Read More

Logo

Targeted Oncology/ FDA Ok’s NDA for SH-105 in Breast and Ovarian Cancer

January 15th 2024January 15th 2024

Read More

Logo

Pharmaceutical Executive/ FDA Accepts New Drug Application for Shorla Oncology’s Novel Treatment for Breast, Ovarian Cancer

January 29th 2024January 12th 2024

Read More

Photo

Shorla Oncology Announces FDA Filing Acceptance of New Drug Application for novel formulation to treat breast and ovarian cancer

January 9th 2024

Read More

Banner

Shorla Oncology attending JP Morgan Healthcare Conference

December 8th 2023

Read More

Rayna

Press Release: Shorla Oncology Welcomes Rayna Sethi Herman as Chief Commercial Officer

December 8th 2023

Read More

Banner

Shorla Oncology at ASH Annual Meeting and Exposition

November 21st 2023

Read More

Older posts
Newer posts
Page1 … Page4 Page5 Page6 … Page10
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

STATE COMPLIANCE PROGRAM DECLARATIONS

Company number: 618033
©SHORLA ONCOLOGY® 2026

© 2026 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.